Information Provided By:
Fly News Breaks for April 26, 2019
Apr 26, 2019 | 06:15 EDT
Goldman Sachs analyst Paul Choi upgraded The Medicines Co. to Buy from Neutral and raised his price target for the shares to $55 from $25. The target implies 90% upside from the current price of $29.80. The analyst says that with the Orion Phase 3 topline results expected in Q3, his comfort level with inclisiran's benefit/risk profile has increased based on the recent updates from the independent data monitoring committee and a separate update for givosiran, which uses the same ESC-GalNAc conjugate platform. Further, new management is taking the appropriate steps to right-size the cost base and capital structure, Choi tells investors in a research note. This sets up inclisiran for a successful launch, which should also increase The Medicines Co.'s potential appeal to partner or strategic buyer, adds the analyst. Choi also thinks near term consensus launch expectations are achievable.
News For MDCO From the Last 2 Days
There are no results for your query MDCO